Effects of donepezil on scopolamine-induced cognitive impairment and Alzheimer’s disease-like change in quantitative EEG analysis in rhesus monkeys

Author(s):  
Tomokazu Nakako
1996 ◽  
Vol 27 (2) ◽  
pp. 69-77 ◽  
Author(s):  
C. J. Stam ◽  
B. Jelles ◽  
H. A. M. Achtereekte ◽  
J. H. van Birgelen ◽  
J. P. J. Slaets

2020 ◽  
Vol 11 (2) ◽  
pp. 81-93
Author(s):  
M. V. Nikolaenko ◽  
E. A. Kizhevatova ◽  
N. V. Drobotya

Objective: to establish the relationship between the presence of cognitive disorders in patients with arterial hypertension and changes in EEG, to assess the dynamics of these changes against the background of various modes of cerebroprotective therapy.Materials and methods: the study involved 92 people with arterial hypertension, whose average age was 63 ± 8.2 years. The research was carried out on the device “Encephalan-EEGR-19/26”. To assess cognitive functions, patients were tested using the MoСA test. Patients with cognitive impairment were divided into three groups of dynamic monitoring with diff erent modes of cerebroprotective therapy.Results: non-specifi c patterns in the slow-wave range were registered in patients with cognitive impairment during visual EEG analysis. In the quantitative analysis of the EEG revealed changes in the frequency and amplitude of the alpha rhythm, the power variation on the basic rhythms, the reduction of the total strength of the rhythms, the increase in relative power of slow rhythms in the frontal leads to the total power of the rhythms. After the treatment, most patients showed an increase in scores on the “Montreal scale”, a decrease in anxiety and depression on the” Hospital scale”, and an increase in the SF-36 index. Quantitative EEG analysis revealed positive dynamics comparable to the clinic and test data. The most favorable EEG dynamics was registered in groups of patients receiving neuroprotective and combined therapy.Conclusions: the results obtained indicate the diagnostic value of quantitative EEG analysis and the feasibility of adding drugs that improve the metabolism and blood supply to the brain to standard antihypertensive therapy.


2021 ◽  
Vol 11 (10) ◽  
pp. 1359
Author(s):  
Una Smailovic ◽  
Charlotte Johansson ◽  
Thomas Koenig ◽  
Ingemar Kåreholt ◽  
Caroline Graff ◽  
...  

The apolipoprotein E (APOE) ε4 allele is a risk factor for Alzheimer’s disease (AD) that has been linked to changes in brain structure and function as well as to different biological subtypes of the disease. The present study aimed to investigate the association of APOE ε4 genotypes with brain functional impairment, as assessed by quantitative EEG (qEEG) in patients on the AD continuum. The study population included 101 amyloid positive patients diagnosed with mild cognitive impairment (MCI) (n = 50) and AD (n = 51) that underwent resting-state EEG recording and CSF Aβ42 analysis. In total, 31 patients were APOE ε4 non-carriers, 42 were carriers of one, and 28 were carriers of two APOE ε4 alleles. Quantitative EEG analysis included computation of the global field power (GFP) and global field synchronization (GFS) in conventional frequency bands. Amyloid positive patients who were carriers of APOE ε4 allele(s) had significantly higher GFP beta and significantly lower GFS in theta and beta bands compared to APOE ε4 non-carriers. Increased global EEG power in beta band in APOE ε4 carriers may represent a brain functional compensatory mechanism that offsets global EEG slowing in AD patients. Our findings suggest that decreased EEG measures of global synchronization in theta and beta bands reflect brain functional deficits related to the APOE ε4 genotype in patients that are on a biomarker-verified AD continuum.


2019 ◽  
Vol 31 (1) ◽  
pp. 111-115 ◽  
Author(s):  
Borislav Radic ◽  
◽  
Ratimir Petrovic ◽  
Anja Golubić ◽  
Ervina Bilic ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document